US Pharma MarketingLilly, Boehringer to slash at least €1B each from planned investments in Germany
Lilly, Boehringer to slash at least €1B each from planned investments in Germany is a pharma and life sciences industry update from FiercePharma. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the country, each by at least $1 billion.
Source: FiercePharma